A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 400,000 shares of TVTX stock, worth $6.96 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
400,000
Previous 400,000 -0.0%
Holding current value
$6.96 Million
Previous $3.29 Million 70.19%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$5.26 - $8.28 $526,000 - $827,999
-100,000 Reduced 20.0%
400,000 $3.29 Million
Q4 2023

Feb 14, 2024

BUY
$5.44 - $9.5 $2.72 Million - $4.75 Million
500,000 New
500,000 $4.5 Million
Q1 2023

May 15, 2023

BUY
$17.82 - $22.89 $27 Million - $34.7 Million
1,513,962 Added 58.23%
4,113,962 $92.5 Million
Q4 2022

Feb 14, 2023

BUY
$18.47 - $26.14 $4.62 Million - $6.54 Million
250,000 Added 10.64%
2,600,000 $54.7 Million
Q3 2022

Nov 14, 2022

BUY
$22.91 - $28.63 $9.16 Million - $11.5 Million
400,000 Added 20.51%
2,350,000 $57.9 Million
Q2 2022

Aug 15, 2022

BUY
$20.94 - $30.01 $9.37 Million - $13.4 Million
447,508 Added 29.78%
1,950,000 $47.2 Million
Q1 2022

May 16, 2022

BUY
$23.61 - $30.6 $4.72 Million - $6.12 Million
200,000 Added 15.36%
1,502,492 $38.7 Million
Q4 2021

Feb 14, 2022

SELL
$24.34 - $31.17 $9.68 Million - $12.4 Million
-397,508 Reduced 23.38%
1,302,492 $40.4 Million
Q3 2021

Nov 15, 2021

SELL
$12.98 - $25.03 $24.6 Million - $47.4 Million
-1,893,763 Reduced 52.7%
1,700,000 $41.2 Million
Q2 2021

Aug 16, 2021

SELL
$14.11 - $26.4 $13.5 Million - $25.2 Million
-956,237 Reduced 21.02%
3,593,763 $52.4 Million
Q1 2021

May 17, 2021

BUY
$23.37 - $31.77 $39.7 Million - $54 Million
1,700,000 Added 59.65%
4,550,000 $114 Million
Q4 2020

Feb 16, 2021

BUY
$19.17 - $27.87 $54.6 Million - $79.4 Million
2,850,000 New
2,850,000 $77.7 Million

Others Institutions Holding TVTX

About Travere Therapeutics, Inc.


  • Ticker TVTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 64,173,600
  • Market Cap $1.12B
  • Description
  • Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...
More about TVTX
Track This Portfolio

Track Adage Capital Partners Gp, L.L.C. Portfolio

Follow Adage Capital Partners Gp, L.L.C. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.